Loading viewer...
earnings
Format: PDF earnings
Teva Pharmaceutical Industries presented fourth quarter and full year 2022 financial results on February 8, 2023, detailing performance across its generic and specialty pharmaceutical portfolio including products such as AUSTEDO, AJOVY, and COPAXONE. The presentation addresses key business challenges including competition in generic markets, substantial debt management, and ongoing litigation matters.
investor_presentation
37 Pages
earnings
32 Pages
EQT Corporation